To assess the effectiveness of topical tapinarof to topical betamethasone in patients with mild to moderate plaque psoriasis presenting to tertiary care hospital in Islamabad
Age 18 years-65 years
Clinically diagnosed plaque psoriasis involving body surface area ( BSA) of 2-20% (mild to moderate severity)
Disease duration of at least 6 months
Willing and able to provide written informed consent
Severe psoriasis (BSA >20% or requiring systemic therapy)
Pregnant and lactating mothers
Known hypersensitivity to Tapinarof or any of its excipients
Concurrent dermatological conditions that may interfere with assessment e.g fungal infections,atopic dermatitis